{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:16:00Z","timestamp":1789902960474,"version":"4.0.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The majority of subjects included in previous tadalafil once-a-day clinical trials were non-na\u00efve to previous phosphodiesterase 5 (PDE5) inhibitors on demand. A study on PDE5 inhibitor na\u00efve subjects was therefore warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of once-a-day tadalafil in PDE5 inhibitor-na\u00efve men with erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcomes Measures<\/jats:title>\n                  <jats:p>Primary efficacy end points were changes from baseline to end point in the International Index of Erectile Function (IIEF) Erectile Function (EF) domain score and the per-subject proportion of \u201cyes\u201d responses to sexual encounter profile (SEP) question 2 (SEP2) and question 3 (SEP3).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PDE5 inhibitor-na\u00efve men with ED (N\u2003=\u2003217) were randomized in a 1:2 ratio to receive placebo or tadalafil 5\u2003mg once a day for 12 weeks. Enrollment began in January 2009 and the last subject completed in January 2010.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At end point, least square mean change from baseline IIEF-EF domain score (7.3 vs. 3.4), SEP2 (23.8% vs. 12.2%) and SEP3 (39.5% vs. 21.5%), was significantly larger for tadalafil vs. placebo (all P\u2003&amp;lt;\u20030.001). The most common adverse events (AEs) in tadalafil-treated subjects were back pain, nasopharyngitis, dyspepsia, headache, and myalgia. Four subjects (2.7%) in the tadalafil group and one subject (1.4%) in the placebo group discontinued because of AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In PDE5 inhibitor-na\u00efve men, tadalafil once a day significantly improved EF compared with placebo. Safety results were consistent with previous tadalafil once-a-day clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2011.02353.x","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T12:21:59Z","timestamp":1309436519000},"page":"2617-2624","source":"Crossref","is-referenced-by-count":28,"title":["A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Once-A-Day Tadalafil in Men with Erectile Dysfunction Who Are Na\u00efve to PDE5 Inhibitors"],"prefix":"10.1093","volume":"8","author":[{"given":"Francesco","family":"Montorsi","sequence":"first","affiliation":[{"name":"Department of Urology, Scientific Institute Hospital San Raffaele , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Aversa","sequence":"additional","affiliation":[{"name":"Department of Medical Pathophysiology, Faculty of Medicine and Surgery, University of Rome \u201cLa Sapienza\u201d , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Moncada","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital La Zarzuela , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Perimenis","sequence":"additional","affiliation":[{"name":"Department of Urology, Patras University Hospital , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Porst","sequence":"additional","affiliation":[{"name":"\u00b6Private Practice of Urology and Andrology , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Barker","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Shane","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sorsaburu","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,9,1]]},"reference":[{"key":"2024032522004366200_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH Consensus Development Panel on Impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA"},{"key":"2024032522004366200_bb0015","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14656561003698131","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction","volume":"11","author":"Dorsey","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"2024032522004366200_bb0020","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"key":"2024032522004366200_bb0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/TCRM.S3336","article-title":"Tadalafil in the treatment of erectile dysfunction","volume":"4","author":"Coward","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2024032522004366200_bb0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11934-003-0027-x","article-title":"Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists","volume":"4","author":"Francis","year":"2003","journal-title":"Curr Urol Rep"},{"key":"2024032522004366200_bb0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1743-6109.04042.x","article-title":"Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil","volume":"1","author":"McMahon","year":"2004","journal-title":"J Sex Med"},{"key":"2024032522004366200_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1743-6109.2005.20360.x","article-title":"Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction","volume":"2","author":"McMahon","year":"2005","journal-title":"J Sex Med"},{"key":"2024032522004366200_bb0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.eururo.2006.02.052","article-title":"Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5\u2003mg and 10\u2003mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Porst","year":"2006","journal-title":"Eur Urol"},{"key":"2024032522004366200_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.ijir.3901496","article-title":"Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US","volume":"19","author":"Rajfer","year":"2007","journal-title":"Int J Impot Res"},{"key":"2024032522004366200_bb0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1464-5491.2007.02338.x","article-title":"Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction","volume":"25","author":"Hatzichristou","year":"2008","journal-title":"Diabet Med"},{"key":"2024032522004366200_bb0060","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/j.1743-6109.2008.00935.x","article-title":"Long-term safety and efficacy of tadalafil 5\u2003mg dosed once daily in men with erectile dysfunction","volume":"5","author":"Porst","year":"2008","journal-title":"J Sex Med"},{"key":"2024032522004366200_bb0065","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1743-6109.2006.00273.x","article-title":"Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate","volume":"3","author":"Broderick","year":"2006","journal-title":"J Sex Med"},{"key":"2024032522004366200_bb0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2009.04.033","article-title":"Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia","volume":"56","author":"Porst","year":"2009","journal-title":"Eur Urol"},{"key":"2024032522004366200_bb0075","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2004.04819.x","article-title":"The efficacy and safety of tadalafil: An update","volume":"93","author":"Carson","year":"2004","journal-title":"BJU Int"},{"key":"2024032522004366200_bb0080","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2005.02.019","article-title":"An evaluation of an alternative dosing regimen with tadalafil, 3 times\/week, for men with erectile dysfunction: SURE study in 14 European countries","volume":"47","author":"Mirone","year":"2005","journal-title":"Eur Urol"},{"key":"2024032522004366200_bb0085","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.2174\/138161206778343046","article-title":"Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction","volume":"12","author":"Aversa","year":"2006","journal-title":"Curr Pharm Des"},{"key":"2024032522004366200_bb0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/ciia.2006.1.4.439","article-title":"Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence","volume":"1","author":"Frajese","year":"2006","journal-title":"Clin Interv Aging"},{"key":"2024032522004366200_bb0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1464-410X.2004.05049.x","article-title":"Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction","volume":"94","author":"Eardley","year":"2004","journal-title":"BJU Int"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515336614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515336614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/9\/2617\/47250083\/jsm_8_9_2617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/9\/2617\/47250083\/jsm_8_9_2617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T22:15:02Z","timestamp":1711404902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/8\/9\/2617\/6844759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,1]]},"published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02353.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,9]]},"published":{"date-parts":[[2011,9,1]]}}}